About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 476279, 19 pages
http://dx.doi.org/10.1155/2010/476279
Review Article

Pathogenesis of Insulin Resistance in Skeletal Muscle

Division of Diabetes, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229, USA

Received 7 December 2009; Accepted 20 January 2010

Academic Editor: Guy M. Benian

Copyright © 2010 Muhammad A. Abdul-Ghani and Ralph A. DeFronzo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. A. DeFronzo, “Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes,” Diabetes Reviews, vol. 5, no. 3, pp. 177–269, 1997. View at Scopus
  2. R. A. DeFronzo, “The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM,” Diabetes, vol. 37, no. 6, pp. 667–687, 1988. View at Scopus
  3. R. A. DeFronzo, “Pathogenesis of type 2 diabetes mellitus,” Medical Clinics of North America, vol. 88, no. 4, pp. 787–835, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. R. A. Defronzo, “From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus,” Diabetes, vol. 58, no. 4, pp. 773–795, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. R. A. DeFronzo, R. Gunnarsson, O. Bjorkman, M. Olsson, and J. Wahren, “Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus,” The Journal of Clinical Investigation, vol. 76, no. 1, pp. 149–155, 1985. View at Scopus
  6. A. Mitrakou, D. Kelley, T. Veneman, et al., “Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM,” Diabetes, vol. 39, no. 11, pp. 1381–1390, 1990. View at Scopus
  7. K. Cusi, K. Maezono, A. Osman, et al., “Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle,” The Journal of Clinical Investigation, vol. 105, no. 3, pp. 311–320, 2000. View at Scopus
  8. M. Bajaj and R. A. DeFronzo, “Metabolic and molecular basis of insulin resistance,” Journal of Nuclear Cardiology, vol. 10, no. 3, pp. 311–323, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Bouzakri, H. A. Koistinen, and J. R. Zierath, “Molecular mechanisms of skeletal muscle insulin resistance in type 2 diabetes,” Current Diabetes Reviews, vol. 1, no. 2, pp. 167–174, 2005. View at Scopus
  10. H. K. R. Karlsson and J. R. Zierath, “Insulin signaling and glucose transport in insulin resistant human skeletal muscle,” Cell Biochemistry and Biophysics, vol. 48, no. 2-3, pp. 103–113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Lettner and M. Roden, “Ectopic fat and insulin resistance,” Current Diabetes Reports, vol. 8, no. 3, pp. 185–191, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. D. McGarry, “Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes,” Diabetes, vol. 51, no. 1, pp. 7–18, 2002. View at Scopus
  13. K. F. Petersen and G. I. Shulman, “Etiology of insulin resistance,” American Journal of Medicine, vol. 119, no. 5, supplement 1, pp. 10S–16S, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. H. Bays, L. Mandarino, and R. A. DeFronzo, “Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 463–478, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Krssak and M. Roden, “The role of lipid accumulation in liver and muscle for insulin resistance and type 2 diabetes mellitus in humans,” Reviews in Endocrine and Metabolic Disorders, vol. 5, no. 2, pp. 127–134, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M. Roden, “Muscle triglycerides and mitochondrial function: possible mechanisms for the development of type 2 diabetes,” International Journal of Obesity, vol. 29, supplement 2, pp. S111–S115, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Morino, K. F. Petersen, and G. I. Shulman, “Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction,” Diabetes, vol. 55, supplement 2, pp. S9–S15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. A. Abdul-Ghani and R. A. DeFronzo, “Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus,” Current Diabetes Reports, vol. 8, no. 3, pp. 173–178, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Højlund, M. Mogensen, K. Sahlin, and H. Beck-Nielsen, “Mitochondrial dysfunction in type 2 diabetes and obesity,” Endocrinology and Metabolism Clinics of North America, vol. 37, no. 3, pp. 713–731, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. B. B. Lowell and G. I. Shulman, “Mitochondrial dysfunction and type 2 diabetes,” Science, vol. 307, no. 5708, pp. 384–387, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. L. C. Groop, R. C. Bonadonna, S. DelPrato, et al., “Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance,” The Journal of Clinical Investigation, vol. 84, no. 1, pp. 205–213, 1989. View at Scopus
  22. E. E. Blaak, “Metabolic fluxes in skeletal muscle in relation to obesity and insulin resistance,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 19, no. 3, pp. 391–403, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. B. Kiens, “Skeletal muscle lipid metabolism in exercise and insulin resistance,” Physiological Reviews, vol. 86, no. 1, pp. 205–243, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. D. Thiebaud, E. Jacot, R. A. DeFronzo, E. Maeder, E. Jequier, and J. P. Felber, “The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man,” Diabetes, vol. 31, no. 11, pp. 957–963, 1982. View at Scopus
  25. H. P. Himsworth and R. B. Kerr, “Insulin-sensitive and insulin-insensitive types of diabetes mellitus,” Clinical Science, vol. 4, pp. 120–152, 1939.
  26. H. Ginsberg, G. Kimmerling, J. M. Olefsky, and G. M. Reaven, “Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia,” The Journal of Clinical Investigation, vol. 55, no. 3, pp. 454–461, 1975. View at Scopus
  27. R. A. DeFronzo, D. Deibert, R. Hendler, P. Felig, and V. Soman, “Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes,” The Journal of Clinical Investigation, vol. 63, no. 5, pp. 939–946, 1979.
  28. R. A. DeFronzo, V. Soman, R. S. Sherwin, R. Hendler, and P. Felig, “Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding,” The Journal of Clinical Investigation, vol. 62, no. 1, pp. 204–213, 1978.
  29. W. J. H. Butterfield and M. J. Whichelow, “Peripheral glucose metabolism in control subjects and diabetic patients during glucose, glucose-insulin and insulin sensitivity tests,” Diabetologia, vol. 1, no. 1, pp. 43–53, 1965. View at Publisher · View at Google Scholar
  30. S. R. Kashyap, R. Belfort, R. Berria, et al., “Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes,” American Journal of Physiology, vol. 287, no. 3, pp. E537–E546, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. K. Danadian, G. Balasekaran, V. Lewy, M. P. Meza, R. Robertson, and S. A. Arslanian, “Insulin sensitivity in African-American children with and without family history of type 2 diabetes,” Diabetes Care, vol. 22, no. 8, pp. 1325–1329, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. K. F. Petersen, S. Dufour, D. Befroy, R. Garcia, and G. I. Shulman, “Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes,” The New England Journal of Medicine, vol. 350, no. 7, pp. 664–671, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. S. E. Kahn, R. L. Hull, and K. M. Utzschneider, “Mechanisms linking obesity to insulin resistance and type 2 diabetes,” Nature, vol. 444, no. 7121, pp. 840–846, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. C. Bogardus, S. Lillioja, D. Mott, G. R. Reaven, A. Kashiwagi, and J. E. Foley, “Relationship between obesity and maximal insulin-stimulated glucose uptake in vivo and in vitro in Pima Indians,” The Journal of Clinical Investigation, vol. 73, no. 3, pp. 800–805, 1984. View at Scopus
  35. E. Ferrannini, G. Buzzigoli, R. Bonadonna, et al., “Insulin resistance in essential hypertension,” The New England Journal of Medicine, vol. 317, no. 6, pp. 350–357, 1987.
  36. P. Bressler, S. R. Bailey, M. Matsuda, and R. A. DeFronzo, “Insulin resistance and coronary artery disease,” Diabetologia, vol. 39, no. 11, pp. 1345–1350, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. R. A. DeFronzo, “Glucose intolerance and aging. Evidence for tissue insensitivity to insulin,” Diabetes, vol. 28, no. 12, pp. 1095–1101, 1979.
  38. M. Lankarani, N. Valizadeh, R. Heshmat, M. Peimani, and F. Sohrabvand, “Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 25, no. 8, pp. 504–507, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. J. L. Bailey, B. Zheng, Z. Hu, S. R. Price, and W. E. Mitch, “Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy,” Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1388–1394, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. J. W. Swan, S. D. Anker, C. Walton, et al., “Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure,” Journal of the American College of Cardiology, vol. 30, no. 2, pp. 527–532, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. J. N. Livingston and R. T. Moxley III, “Myotonic dystrophy—phenotype-genotype and insulin resistance,” Diabetes Reviews, vol. 2, no. 1, pp. 29–42, 1994.
  42. V. Simha and A. Garg, “Lipodystrophy: lessons in lipid and energy metabolism,” Current Opinion in Lipidology, vol. 17, no. 2, pp. 162–169, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. S. J. Van Cromphaut, I. Vanhorebeek, and G. Van den Berghe, “Glucose metabolism and insulin resistance in sepsis,” Current Pharmaceutical Design, vol. 14, no. 19, pp. 1887–1899, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Pagano, P. Cavallo-Perin, M. Cassader, et al., “An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects,” The Journal of Clinical Investigation, vol. 72, no. 5, pp. 1814–1820, 1983. View at Scopus
  45. P. W. Hruz, “HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models,” Current Opinion in HIV and AIDS, vol. 3, no. 6, pp. 660–665, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. S. Jacob, K. Rett, M. Wicklmayr, B. Agrawal, H. J. Augustin, and G.-J. Dietze, “Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study,” Journal of Hypertension, vol. 14, no. 4, pp. 489–494, 1996. View at Scopus
  47. R. Jani, M. Molina, M. Matsuda, et al., “Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range,” Diabetes Care, vol. 31, no. 2, pp. 311–315, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. R. A. DeFronzo, “Insulin secretion, insulin resistance, and obesity,” International Journal of Obesity, vol. 6, supplement 1, pp. 73–82, 1982.
  49. A. Lemay, L. Turcot, F. Déchêne, S. Dodin, and J. C. Forest, “Hyperinsulinemia in nonobese women reporting a moderate weight gain at the beginning of menopause: a useful early measure of susceptibility to insulin resistance,” Menopause, vol. 17, no. 2, pp. 321–325, 2010.
  50. N. M. Wedick, M. B. Snijder, J. M. Dekker, et al., “Prospective investigation of metabolic characteristics in relation to weight gain in older adults: the hoorn study,” Obesity, vol. 17, no. 8, pp. 1609–1614, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. J. Erdmann, B. Kallabis, U. Oppel, O. Sypchenko, S. Wagenpfeil, and V. Schusdziarra, “Development of hyperinsulinemia and insulin resistance during the early stage of weight gain,” American Journal of Physiology, vol. 294, no. 3, pp. E568–E575, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. P. Schrauwen, “High-fat diet, muscular lipotoxicity and insulin resistance,” Proceedings of the Nutrition Society, vol. 66, no. 1, pp. 33–41, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. D. A. Pan, S. Lillioja, A. D. Kriketos, et al., “Skeletal muscle triglyceride levels are inversely related to insulin action,” Diabetes, vol. 46, no. 6, pp. 983–988, 1997.
  54. D. I. W. Phillips, S. Caddy, V. Ilic, et al., “Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects,” Metabolism, vol. 45, no. 8, pp. 947–950, 1996. View at Publisher · View at Google Scholar
  55. G. Perseghin, P. Scifo, F. De Cobelli, et al., “Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents,” Diabetes, vol. 48, no. 8, pp. 1600–1606, 1999. View at Publisher · View at Google Scholar
  56. M. Krssak, K. Falk Petersen, A. Dresner, et al., “Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study,” Diabetologia, vol. 42, no. 1, pp. 113–116, 1999. View at Publisher · View at Google Scholar
  57. G. M. Reaven, “Role of insulin resistance in human disease,” Diabetes, vol. 37, no. 12, pp. 1595–1607, 1988.
  58. A. H. Mokdad, E. S. Ford, B. A. Bowman, et al., “Diabetes trends in the U.S.: 1990–1998,” Diabetes Care, vol. 23, no. 9, pp. 1278–1283, 2000.
  59. L. C. Groop, C. Saloranta, M. Shank, R. C. Bonadonna, E. Ferrannini, and R. A. DeFronzo, “The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 72, no. 1, pp. 96–107, 1991.
  60. G. M. Reaven, C. Hollenbeck, C.-Y. Jeng, M. S. Wu, and Y.-D. I. Chen, “Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM,” Diabetes, vol. 37, no. 8, pp. 1020–1024, 1988.
  61. G. Perseghin, S. Ghosh, K. Gerow, and G. I. Shulman, “Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study,” Diabetes, vol. 46, no. 6, pp. 1001–1009, 1997.
  62. M. E. Griffin, M. J. Marcucci, G. W. Cline, et al., “Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade,” Diabetes, vol. 48, no. 6, pp. 1270–1274, 2000. View at Publisher · View at Google Scholar
  63. A. Dresner, D. Laurent, M. Marcucci, et al., “Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity,” The Journal of Clinical Investigation, vol. 103, no. 2, pp. 253–259, 1999.
  64. C. Yu, Y. Chen, G. W. Cline, et al., “Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle,” The Journal of Biological Chemistry, vol. 277, no. 52, pp. 50230–50236, 2002. View at Publisher · View at Google Scholar · View at PubMed
  65. R. Belfort, L. Mandarino, S. Kashyap, et al., “Dose-response effect of elevated plasma free fatty acid on insulin signaling,” Diabetes, vol. 54, no. 6, pp. 1640–1648, 2005. View at Publisher · View at Google Scholar
  66. S. I. Itani, N. B. Ruderman, F. Schmieder, and G. Boden, “Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α,” Diabetes, vol. 51, no. 7, pp. 2005–2011, 2002.
  67. D. K. Richardson, S. Kashyap, M. Bajaj, et al., “Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle,” The Journal of Biological Chemistry, vol. 280, no. 11, pp. 10290–10297, 2005. View at Publisher · View at Google Scholar · View at PubMed
  68. G. Boden and X. Chen, “Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes,” The Journal of Clinical Investigation, vol. 96, no. 3, pp. 1261–1268, 1995.
  69. M. Bajaj, S. Suraamornkul, A. Romanelli, et al., “Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty acyl-CoAs and insulin action in type 2 diabetic patients,” Diabetes, vol. 54, no. 11, pp. 3148–3153, 2005. View at Publisher · View at Google Scholar
  70. M. Bajaj, S. Suraamornkul, S. Kashyap, K. Cusi, L. Mandarino, and R. A. DeFronzo, “Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4649–4655, 2004. View at Publisher · View at Google Scholar · View at PubMed
  71. A. Vaag, P. Skott, P. Damsbo, M.-A. Gall, E. A. Richter, and H. Beck-Nielsen, “Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus,” The Journal of Clinical Investigation, vol. 88, no. 4, pp. 1282–1290, 1991.
  72. A. T. M. G. Santomauro, G. Boden, M. E. R. Silva, et al., “Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects,” Diabetes, vol. 48, no. 9, pp. 1836–1841, 1999. View at Publisher · View at Google Scholar
  73. R. H. Unger, “Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications,” Diabetes, vol. 44, no. 8, pp. 863–870, 1995.
  74. G. Boden, B. Lebed, M. Schatz, C. Homko, and S. Lemieux, “Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects,” Diabetes, vol. 50, no. 7, pp. 1612–1617, 2001.
  75. L. H. Storlien, A. B. Jenkins, D. J. Chisholm, W. S. Pascoe, S. Khouri, and E. W. Kraegen, “Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and ω-3 fatty acids in muscle phospholipid,” Diabetes, vol. 40, no. 2, pp. 280–289, 1991.
  76. M. J. Pagliassotti, D. Pan, P. Prach, T. Koppenhafer, L. Storlien, and J. O. Hill, “Tissue oxidative capacity, fuel stores and skeletal muscle fatty acid composition in obesity-prone and obesity-resistant rats,” Obesity Research, vol. 3, no. 5, pp. 459–464, 1995.
  77. T. Yamauchi, J. Kamon, H. Waki, et al., “The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity,” Nature Medicine, vol. 7, no. 8, pp. 941–946, 2001. View at Publisher · View at Google Scholar · View at PubMed
  78. J. K. Kim, J. J. Fillmore, Y. Chen, et al., “Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 13, pp. 7522–7527, 2001. View at Publisher · View at Google Scholar · View at PubMed
  79. A. V. Greco, G. Mingrone, A. Giancaterini, et al., “Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion,” Diabetes, vol. 51, no. 1, pp. 144–151, 2002.
  80. R. A. DeFronzo and E. Ferrannini, “Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease,” Diabetes Care, vol. 14, no. 3, pp. 173–194, 1991.
  81. R. A. DeFronzo, “Insulin resistance: the metabolic link between non-insulin-dependent diabetes mellitus, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease,” Current Opinion in Cardiology, vol. 5, no. 5, pp. 586–593, 1990.
  82. N. Abumrad, C. Coburn, and A. Ibrahimi, “Membrane proteins implicated in long-chain fatty acid uptake by mammalian cells: CD36, FATP and FABPm,” Biochimica et Biophysica Acta, vol. 1441, no. 1, pp. 4–13, 1999. View at Publisher · View at Google Scholar
  83. A. Bonen, C. R. Benton, S. E. Campbell, et al., “Plasmalemmal fatty acid transport is regulated in heart and skeletal muscle by contraction, insulin and leptin, and in obesity and diabetes,” Acta Physiologica Scandinavica, vol. 178, no. 4, pp. 347–356, 2003. View at Publisher · View at Google Scholar
  84. H. J. Pownall and J. A. Hamilton, “Energy translocation across cell membranes and membrane models,” Acta Physiologica Scandinavica, vol. 178, no. 4, pp. 357–365, 2003. View at Publisher · View at Google Scholar
  85. L. Hagenfeldt, “Metabolism of free fatty acids and ketone bodies during exercise in normal and diabetic man,” Diabetes, vol. 28, supplement 1, pp. 66–70, 1979.
  86. L. Hagenfeldt and J. Wahren, “Human forearm muscle metabolism during exercise. II. Uptake, release and oxidation of individual FFA and glycerol,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 21, no. 3, pp. 263–276, 1968.
  87. R. J. Havel, L. G. Ekelund, and A. Holmgren, “Kinetic analysis of the oxidation of palmitate-1-14C in man during prolonged heavy muscular exercise,” Journal of Lipid Research, vol. 8, no. 4, pp. 366–373, 1967.
  88. B. Kiens, B. Essen-Gustavsson, N. J. Christensen, and B. Saltin, “Skeletal muscle substrate utilization during submaximal exercise in man: effect of endurance training,” Journal of Physiology, vol. 469, pp. 459–478, 1993.
  89. C. E. Gargiulo, S. M. Stunlsatz-Krouper, and J. E. Schaffer, “Localization of adipocyte long-chain fatty acyl-CoA synthetase at the plasma membrane,” Journal of Lipid Research, vol. 40, no. 5, pp. 881–892, 1999.
  90. A. Ibrahimi, A. Bonen, W. D. Blinn, et al., “Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin,” The Journal of Biological Chemistry, vol. 274, no. 38, pp. 26761–26766, 1999. View at Publisher · View at Google Scholar
  91. M. Febbraio, N. A. Abumrad, D. P. Hajjar, et al., “A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism,” The Journal of Biological Chemistry, vol. 274, no. 27, pp. 19055–19062, 1999. View at Publisher · View at Google Scholar
  92. J. J. F. P. Luiken, Y. Arumugam, D. J. Dyck, et al., “Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats,” The Journal of Biological Chemistry, vol. 276, no. 44, pp. 40567–40573, 2001. View at Publisher · View at Google Scholar · View at PubMed
  93. G. R. Steinberg, D. J. Dyck, J. Calles-Escandon, et al., “Chronic leptin administration decreases fatty acid uptake and fatty acid transporters in rat skeletal muscle,” The Journal of Biological Chemistry, vol. 277, no. 11, pp. 8854–8860, 2002. View at Publisher · View at Google Scholar · View at PubMed
  94. D. Cameron-Smith, L. M. Burke, D. J. Angus, et al., “A short-term, high-fat diet up-regulates lipid metabolism and gene expression in human skeletal muscle,” American Journal of Clinical Nutrition, vol. 77, no. 2, pp. 313–318, 2003.
  95. C. Roepstorff, J. W. Helge, B. Vistisen, and B. Kiens, “Studies of plasma membrane fatty acid-binding protein and other lipid-binding proteins in human skeletal muscle,” Proceedings of the Nutrition Society, vol. 63, no. 2, pp. 239–244, 2004. View at Publisher · View at Google Scholar · View at PubMed
  96. A. Bonen, M. L. Parolin, G. R. Steinberg, et al., “Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport increased sarcolemmal FAT/CD36,” FASEB Journal, vol. 18, no. 10, pp. 1144–1146, 2004. View at Publisher · View at Google Scholar · View at PubMed
  97. B. Kiens, T. H. M. Roemen, and G. J. Van der Vusse, “Muscular long-chain fatty acid content during graded exercise in humans,” American Journal of Physiology, vol. 276, no. 2, pp. E352–E357, 1999.
  98. C. Roepstorff, B. Vistisen, K. Roepstorff, and B. Kiens, “Regulation of plasma long-chain fatty acid oxidation in relation to uptake in human skeletal muscle during exercise,” American Journal of Physiology, vol. 287, no. 4, pp. E696–E705, 2004. View at Publisher · View at Google Scholar · View at PubMed
  99. S. S. Jain, A. Chabowski, L. A. Snook, et al., “Additive effects of insulin and muscle contraction on fatty acid transport and fatty acid transporters, FAT/CD36, FABPpm, FATP1, 4 and 6,” FEBS Letters, vol. 583, no. 13, pp. 2294–2300, 2009. View at Publisher · View at Google Scholar · View at PubMed
  100. D. E. Kelley, B. Goodpaster, R. R. Wing, and J.-A. Simoneau, “Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss,” American Journal of Physiology, vol. 277, no. 6, pp. E1130–E1141, 1999.
  101. M. W. Hulver, J. R. Berggren, R. N. Cortright, et al., “Skeletal muscle lipid metabolism with obesity,” American Journal of Physiology, vol. 284, no. 4, pp. E741–E747, 2003.
  102. G. R. Steinberg, M. L. Parolin, G. J. F. Heigenhauser, and D. J. Dyck, “Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance,” American Journal of Physiology, vol. 283, no. 1, pp. E187–E192, 2002.
  103. L. P. Turcotte, J. R. Swenberger, M. Z. Tucker, and A. J. Yee, “Increased fatty acid uptake and altered fatty acid metabolism in insulin-resistant muscle of obese Zucker rats,” Diabetes, vol. 50, no. 6, pp. 1389–1396, 2001.
  104. D. E. Befroy, K. F. Petersen, S. Dufour, et al., “Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients,” Diabetes, vol. 56, no. 5, pp. 1376–1381, 2007. View at Publisher · View at Google Scholar · View at PubMed
  105. J. Szendroedi, A. I. Schmid, M. Chmelik, et al., “Muscle mitochondrial ATP synthesis and glucose transport/phosphorylation in type 2 diabetes,” PLoS Medicine, vol. 4, no. 5, article e154, 2007. View at Publisher · View at Google Scholar · View at PubMed
  106. K. F. Petersen, S. Dufour, and G. I. Shulman, “Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents,” PLoS Medicine, vol. 2, no. 9, article e233, 2005. View at Publisher · View at Google Scholar · View at PubMed
  107. M. Scheuermann-Freestone, P. L. Madsen, D. Manners, et al., “Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes,” Circulation, vol. 107, no. 24, pp. 3040–3046, 2003. View at Publisher · View at Google Scholar · View at PubMed
  108. V. B. Schrauwen-Hinderling, M. E. Kooi, M. K. C. Hesselink, et al., “Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects,” Diabetologia, vol. 50, no. 1, pp. 113–120, 2007. View at Publisher · View at Google Scholar · View at PubMed
  109. K. F. Petersen, D. Befroy, S. Dufour, et al., “Mitochondrial dysfunction in the elderly: possible role in insulin resistance,” Science, vol. 300, no. 5622, pp. 1140–1142, 2003. View at Publisher · View at Google Scholar · View at PubMed
  110. A. Brehm, M. Krssak, A. I. Schmid, P. Nowotny, W. Waldhäusl, and M. Roden, “Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle,” Diabetes, vol. 55, no. 1, pp. 136–140, 2006. View at Publisher · View at Google Scholar
  111. K. Morino, K. F. Petersen, S. Dufour, et al., “Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents,” The Journal of Clinical Investigation, vol. 115, no. 12, pp. 3587–3593, 2005. View at Publisher · View at Google Scholar · View at PubMed
  112. V. B. Ritov, E. V. Menshikova, J. He, R. E. Ferrell, B. H. Goodpaster, and D. E. Kelley, “Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes,” Diabetes, vol. 54, no. 1, pp. 8–14, 2005. View at Publisher · View at Google Scholar
  113. M. E. Patti, A. J. Butte, S. Crunkhorn, et al., “Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8466–8471, 2003. View at Publisher · View at Google Scholar · View at PubMed
  114. A. P. Rolo and C. M. Palmeira, “Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress,” Toxicology and Applied Pharmacology, vol. 212, no. 2, pp. 167–178, 2006. View at Publisher · View at Google Scholar · View at PubMed
  115. R. Boushel, E. Gnaiger, P. Schjerling, M. Skovbro, R. Kraunsøe, and F. Dela, “Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle,” Diabetologia, vol. 50, no. 4, pp. 790–796, 2007. View at Publisher · View at Google Scholar · View at PubMed
  116. Y. W. Asmann, C. S. Stump, K. R. Short, et al., “Skeletal muscle mitochondrial functions, mitochondrial DNA copy numbers, and gene transcript profiles in type 2 diabetic and nondiabetic subjects at equal levels of low or high insulin and euglycemia,” Diabetes, vol. 55, no. 12, pp. 3309–3319, 2006. View at Publisher · View at Google Scholar · View at PubMed
  117. A. Chavez-Velazquez, R. Jani, M. A. Abdul-Ghani, et al., “Short-Term Elevation of plasma free fatty acids (FFA) decreases skeletal muscle mitochondrial membrane motential in healthy glucose tolerant subjects,” Diabetes, vol. 56, supplement 1, 2007.
  118. D. E. Kelley, J. He, E. V. Menshikova, and V. B. Ritov, “Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes,” Diabetes, vol. 51, no. 10, pp. 2944–2950, 2002.
  119. F. G. S. Toledo, S. Watkins, and D. E. Kelley, “Changes induced by physical activity and weight loss in the morphology of intermyofibrillar mitochondria in obese men and women,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 3224–3227, 2006. View at Publisher · View at Google Scholar · View at PubMed
  120. M. A. Abdul-Ghani, R. Jani, M. Molina, A. Chavez, D. Tripathy, and R. A. DeFronzo, “Decreased mitochondrial ATP synthesis in obese non-diabetic subjects,” Diabetes, vol. 56, supplement 1, 2008.
  121. E. Phielix, V. B. Schrauwen-Hinderling, M. Mensink, et al., “Lower intrinsic ADP-stimulated mitochondrial respiration underlies in vivo mitochondrial dysfunction in muscle of male type 2 diabetic patients,” Diabetes, vol. 57, no. 11, pp. 2943–2949, 2008. View at Publisher · View at Google Scholar · View at PubMed
  122. M. Mogensen, K. Sahlin, M. Fernström, et al., “Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes,” Diabetes, vol. 56, no. 6, pp. 1592–1599, 2007. View at Publisher · View at Google Scholar · View at PubMed
  123. B. H. Goodpaster, A. Katsiaras, and D. E. Kelley, “Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity,” Diabetes, vol. 52, no. 9, pp. 2191–2197, 2003. View at Publisher · View at Google Scholar
  124. A. V. Greco, G. Mingrone, A. Giancaterini, et al., “Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion,” Diabetes, vol. 51, no. 1, pp. 144–151, 2002.
  125. S. A. Jubrias, P. C. Esselman, L. B. Price, M. E. Cress, and K. E. Conley, “Large energetic adaptations of elderly muscle to resistance and endurance training,” Journal of Applied Physiology, vol. 90, no. 5, pp. 1663–1670, 2001.
  126. J. O. Holloszy and E. F. Coyle, “Adaptations of skeletal muscle to endurance exercise and their metabolic consequences,” Journal of Applied Physiology Respiratory Environmental and Exercise Physiology, vol. 56, no. 4, pp. 831–838, 1984.
  127. P. D. Chilibeck, D. G. Syrotuik, and G. J. Bell, “The effect of concurrent endurance and strength training on quantitative estimates of subsarcolemmal and intermyofibrillar mitochondria,” International Journal of Sports Medicine, vol. 23, no. 1, pp. 33–39, 2002. View at Publisher · View at Google Scholar · View at PubMed
  128. T. Østergård, J. L. Andersen, B. Nyholm, et al., “Impact of exercise training on insulin sensitivity, physical fitness, and muscle oxidative capacity in first-degree relatives of type 2 diabetic patients,” American Journal of Physiology, vol. 290, no. 5, pp. E998–E1005, 2006. View at Publisher · View at Google Scholar · View at PubMed
  129. E. V. Menshikova, V. B. Ritov, F. G. S. Toledo, R. E. Ferrell, B. H. Goodpaster, and D. E. Kelley, “Effects of weight loss and physical activity on skeletal muscle mitochondrial function in obesity,” American Journal of Physiology, vol. 288, no. 4, pp. E818–E825, 2005. View at Publisher · View at Google Scholar · View at PubMed
  130. K. R. Short, J. L. Vittone, M. L. Bigelow, et al., “Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidative capacity,” Diabetes, vol. 52, no. 8, pp. 1888–1896, 2003. View at Publisher · View at Google Scholar
  131. A. O. Chavez, S. Kamath, R. Jani, et al., “Effect of short-term free fatty acids elevation on mitochondrial function in skeletal muscle of healthy individuals,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 1, pp. 422–429, 2010. View at Publisher · View at Google Scholar · View at PubMed
  132. M. A. Abdul-Ghani, F. Muller, Y. Liu, et al., “Deleterious effect of elevated fatty acid metabolites concentration on skeletal muscle mitochondrial ATP synthesis,” Diabetes, vol. 56, supplement 1, 2007.
  133. C. R. Benton, J. G. Nickerson, J. Lally, et al., “Modest PGC-1α overexpression in muscle in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in subsarcolemmal, not intermyofibrillar, mitochondria,” The Journal of Biological Chemistry, vol. 283, no. 7, pp. 4228–4240, 2008. View at Publisher · View at Google Scholar · View at PubMed
  134. M. Lagouge, C. Argmann, Z. Gerhart-Hines, et al., “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α,” Cell, vol. 127, no. 6, pp. 1109–1122, 2006. View at Publisher · View at Google Scholar · View at PubMed
  135. J. H. Lim, J. I. Lee, Y. H. Suh, W. Kim, J. H. Song, and M. H. Jung, “Mitochondrial dysfunction induces aberrant insulin signalling and glucose utilisation in murine C2C12 myotube cells,” Diabetologia, vol. 49, no. 8, pp. 1924–1936, 2006. View at Publisher · View at Google Scholar · View at PubMed
  136. A. E. Brown, M. Elstner, S. J. Yeaman, D. M. Turnbull, and M. Walker, “Does impaired mitochondrial function affect insulin signaling and action in cultured human skeletal muscle cells?” American Journal of Physiology, vol. 294, no. 1, pp. E97–E102, 2008. View at Publisher · View at Google Scholar · View at PubMed
  137. J. A. Pospisilik, C. Knauf, N. Joza, et al., “Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes,” Cell, vol. 131, no. 3, pp. 476–491, 2007. View at Publisher · View at Google Scholar · View at PubMed
  138. A. R. Saltiel and C. R. Kahn, “Insulin signalling and the regulation of glucose and lipid metabolism,” Nature, vol. 414, no. 6865, pp. 799–806, 2001. View at Publisher · View at Google Scholar · View at PubMed
  139. J. E. Pessin and A. R. Saltiel, “Signaling pathways in insulin action: molecular targets of insulin resistance,” The Journal of Clinical Investigation, vol. 106, no. 2, pp. 165–169, 2000.
  140. J. P. Whitehead, S. F. Clark, B. Ursø, and D. E. James, “Signalling through the insulin receptor,” Current Opinion in Cell Biology, vol. 12, no. 2, pp. 222–228, 2000. View at Publisher · View at Google Scholar
  141. L. Ellis, E. Clauser, D. O. Morgan, M. Edery, R. A. Roth, and W. J. Rutter, “Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose,” Cell, vol. 45, no. 5, pp. 721–732, 1986.
  142. C. K. Chou, T. J. Dull, and D. S. Russell, “Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin,” The Journal of Biological Chemistry, vol. 262, no. 4, pp. 1842–1847, 1987.
  143. A. Virkamäki, K. Ueki, and C. R. Kahn, “Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance,” The Journal of Clinical Investigation, vol. 103, no. 7, pp. 931–943, 1999.
  144. X. J. Sun, M. Miralpeix, M. G. Myers Jr., et al., “Expression and function of IRS-1 in insulin signal transmission,” Journal of Biological Chemistry, vol. 267, no. 31, pp. 22662–22672, 1992.
  145. D. Cross, D. Alessi, J. Vandenheed, H. McDowell, H. Hundal, and P. Cohen, “The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin but not rapamycin,” Biochemical Journal, vol. 267, pp. 303–321, 1994.
  146. H. Osawa, C. Sutherland, R. B. Robey, R. L. Printz, and D. K. Granner, “Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin,” The Journal of Biological Chemistry, vol. 271, no. 28, pp. 16690–16694, 1996. View at Publisher · View at Google Scholar
  147. D. F. Lazar, R. J. Wiese, M. J. Brady, et al., “Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin,” The Journal of Biological Chemistry, vol. 270, no. 35, pp. 20801–20807, 1995. View at Publisher · View at Google Scholar
  148. P. Dent, A. Lavoinne, S. Nakielny, F. B. Caudwell, P. Watt, and P. Cohen, “The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle,” Nature, vol. 348, no. 6299, pp. 302–308, 1990. View at Publisher · View at Google Scholar · View at PubMed
  149. C. B. Newgard, M. J. Brady, R. M. O'Doherty, and A. R. Saltiel, “Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1,” Diabetes, vol. 49, no. 12, pp. 1967–1977, 2000.
  150. P. R. Shepherd, B. T. Nave, and K. Siddle, “Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3-L1 adipocytes: evidence for the involvement of phosphoinositide 3-kinase and p70 ribosomal protein-56 kinase,” Biochemical Journal, vol. 305, no. 1, pp. 25–28, 1995.
  151. G. R. Freidenberg, R. R. Henry, H. H. Klein, D. R. Reichart, and J. M. Olefsky, “Decreased kinase activity of insulin receptors from adipocytes of non-insulin-dependent diabetic subjects,” Journal of Clinical Investigation, vol. 79, no. 1, pp. 240–250, 1987.
  152. J. F. Caro, M. K. Sinha, S. M. Raju, et al., “Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes,” The Journal of Clinical Investigation, vol. 79, no. 5, pp. 1330–1337, 1987.
  153. J. F. Caro, O. Ittoop, W. J. Pories, et al., “Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity,” The Journal of Clinical Investigation, vol. 78, no. 1, pp. 249–258, 1986.
  154. V. Trischitta, A. Brunetti, A. Chiavetta, L. Benzi, V. Papa, and R. Vigneri, “Defects in insulin-receptor internalization and processing in monocytes of obese subjects and obese NIDDM patients,” Diabetes, vol. 38, no. 12, pp. 1579–1584, 1989.
  155. H. H. Klein, H. Vestergaard, G. Kotzke, and O. Pedersen, “Elevation of serum insulin concentration during euglycemic hyperinsulinemic clamp studies leads to similar activation of insulin receptor kinase in skeletal muscle of subjects with and without NIDDM,” Diabetes, vol. 44, no. 11, pp. 1310–1317, 1995.
  156. A. Kashiwagi, M. A. Verso, and J. Andrews, “In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus,” The Journal of Clinical Investigation, vol. 72, no. 4, pp. 1246–1254, 1983.
  157. P. Lonnroth, M. Digirolamo, M. Krotkiewski, and U. Smith, “Insulin binding and responsiveness in fat cells from patients with reduced glucose tolerance and type II diabetes,” Diabetes, vol. 32, no. 8, pp. 748–754, 1983.
  158. J. M. Olefsky and G. M. Reaven, “Insulin binding in diabetes. Relationships with plasma insulin levels and insulin sensitivity,” Diabetes, vol. 26, no. 7, pp. 680–688, 1977.
  159. D. E. Moller, A. Yokota, and J. S. Flier, “Normal insulin-receptor cDNA sequence in Pima Indians with NIDDM,” Diabetes, vol. 38, no. 11, pp. 1496–1500, 1989.
  160. J. Kusari, U. S. Verma, J. B. Buse, R. R. Henry, and J. M. Olefsky, “Analysis of the gene sequences of the insulin receptor and the insulin-sensitive glucose transporter (GLUT-4) in patients with common-type non-insulin-dependent diabetes mellitus,” The Journal of Clinical Investigation, vol. 88, no. 4, pp. 1323–1330, 1991.
  161. J. J. Nolan, G. Freidenberg, R. Henry, D. Reichart, and J. M. Olefsky, “Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity,” Journal of Clinical Endocrinology and Metabolism, vol. 78, no. 2, pp. 471–477, 1994. View at Publisher · View at Google Scholar
  162. G. R. Freidenberg, D. Reichart, J. M. Olefsky, and R. R. Henry, “Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss,” The Journal of Clinical Investigation, vol. 82, no. 4, pp. 1398–1406, 1988.
  163. M. Kellerer, G. Kroder, S. Tippmer, et al., “Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts,” Diabetes, vol. 43, no. 3, pp. 447–453, 1994.
  164. W. Pratipanawatr, T. Pratipanawatr, K. Cusi, et al., “Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation,” Diabetes, vol. 50, no. 7–12, pp. 2572–2578, 2001.
  165. A. Krook, M. Björnholm, D. Galuska, et al., “Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients,” Diabetes, vol. 49, no. 2, pp. 284–292, 2000.
  166. Y.-B. Kim, S. E. Nikoulina, T. P. Ciaraldi, R. R. Henry, and B. B. Kahn, “Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes,” The Journal of Clinical Investigation, vol. 104, no. 6, pp. 733–741, 1999.
  167. F. Andreelli, M. Laville, P.-H. Ducluzeau, et al., “Defective regulation of phosphatidylinositol-3-kinase gene expression in skeletal muscle and adipose tissue of non-insulin-dependent diabetes mellitus patients,” Diabetologia, vol. 42, no. 3, pp. 358–364, 1999. View at Publisher · View at Google Scholar
  168. F. Folli, M. J. A. Saad, J. M. Backer, and C. R. Kahn, “Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus,” The Journal of Clinical Investigation, vol. 92, no. 4, pp. 1787–1794, 1993.
  169. K. Morino, S. Neschen, S. Bilz, et al., “Muscle-pecific IRS-1 serala transgenic mice are protected from fat-induced insulin resistance in skeletal muscle,” Diabetes, vol. 57, no. 10, pp. 2644–2651, 2008. View at Publisher · View at Google Scholar · View at PubMed
  170. G. A. Hitman, K. Hawrami, M. I. McCarthy, et al., “Insulin receptor substrate-1 gene mutations in NIDDM; implications for the study of polygenic disease,” Diabetologia, vol. 38, no. 4, pp. 481–486, 1995. View at Publisher · View at Google Scholar
  171. A. Dresner, D. Laurent, M. Marcucci, et al., “Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity,” The Journal of Clinical Investigation, vol. 103, no. 2, pp. 253–259, 1999.
  172. W. A. Khan, G. C. Blobe, and Y. A. Hannun, “Arachidonic acid and free fatty acids as second messengers and the role of protein kinase C,” Cellular Signalling, vol. 7, no. 3, pp. 171–184, 1995. View at Publisher · View at Google Scholar
  173. C. Yu, Y. Chen, G. W. Cline, et al., “Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle,” The Journal of Biological Chemistry, vol. 277, no. 52, pp. 50230–50236, 2002. View at Publisher · View at Google Scholar · View at PubMed
  174. C. Schmitz-Peiffer, C. L. Browne, N. D. Oakes, et al., “Alterations in the expression and cellular localization of protein kinase C isozymes ε and θ are associated with insulin resistance in skeletal muscle of the high-fat-fed rat,” Diabetes, vol. 46, no. 2, pp. 169–178, 1997.
  175. C. Schmitz-Peiffer, N. D. Oakes, C. L. Browne, E. W. Kraegen, and T. J. Biden, “Reversal of chronic alterations of skeletal muscle protein kinase C from fat-fed rats by BRL-49653,” American Journal of Physiology, vol. 273, no. 5, pp. E915–E921, 1997.
  176. T. K. Lam, H. Yoshii, C. A. Haber, et al., “Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta,” Am J Physiol Endocrinol Metab, vol. 283, no. 4, pp. E682–91, 2002.
  177. J.-F. Tanti and J. Jager, “Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation,” Current Opinion in Pharmacology, vol. 9, no. 6, pp. 753–762, 2009. View at Publisher · View at Google Scholar · View at PubMed
  178. H. Sell, J. Eckel, and D. Dietze-Schroeder, “Pathways leading to muscle insulin resistance—the muscle-fat connection,” Archives of Physiology and Biochemistry, vol. 112, no. 2, pp. 105–113, 2006. View at Publisher · View at Google Scholar · View at PubMed
  179. W. A. Hsueh and R. E. Law, “Insulin signaling in the arterial wall,” American Journal of Cardiology, vol. 84, no. 1 A, pp. 21J–24J, 1999.
  180. Z. Y. Jiang, Y.-W. Lin, A. Clemont, et al., “Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats,” The Journal of Clinical Investigation, vol. 104, no. 4, pp. 447–457, 1999.
  181. P. R. Shepherd and B. B. Kahn, “Glucose transporters and insulin action: implications for insulin resistance and diabetes mellitus,” The New England Journal of Medicine, vol. 341, no. 4, pp. 248–257, 1999. View at Publisher · View at Google Scholar
  182. S. J. Hunter and W. T. Garvey, “Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system,” American Journal of Medicine, vol. 105, no. 4, pp. 331–345, 1998. View at Publisher · View at Google Scholar
  183. G. I. Bell, T. Kayano, J. B. Buse, et al., “Molecular biology of mammalian glucose transporters,” Diabetes Care, vol. 13, no. 3, pp. 198–208, 1990.
  184. H.-G. Joost, G. I. Bell, J. D. Best, et al., “Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators,” American Journal of Physiology, vol. 282, no. 4, pp. E974–E976, 2002.
  185. C. A. Stuart, M. E. A. Howell, Y. Zhang, and D. Yin, “Insulin-stimulated translocation of glucose transporter (GLUT) 12 parallels that of GLUT4 in normal muscle,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 9, pp. 3535–3542, 2009. View at Publisher · View at Google Scholar · View at PubMed
  186. P. A. Rogers, R. A. Fisher, and H. Harris, “An electrophoretic study of the distribution and properties of human hexokinases,” Biochemical Genetics, vol. 13, no. 11-12, pp. 857–866, 1975.
  187. W. T. Garvey, T. P. Huecksteadt, S. Matthaei, and J. M. Olefsky, “Role of glucose transporters in the cellular insulin resistance of type II non-insulin-dependent diabetes mellitus,” The Journal of Clinical Investigation, vol. 81, no. 5, pp. 1528–1536, 1988.
  188. J. R. Zierath, L. He, A. Gumà, E. Odegaard Wahlström, A. Klip, and H. Wallberg-Henriksson, “Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM,” Diabetologia, vol. 39, no. 10, pp. 1180–1189, 1996.
  189. A. Krook, M. Björnholm, D. Galuska, et al., “Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients,” Diabetes, vol. 49, no. 2, pp. 284–292, 2000.
  190. O. Pedersen, J. F. Bak, P. H. Andersen, et al., “Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity for NIDDM,” Diabetes, vol. 39, no. 7, pp. 865–870, 1990.
  191. J. Eriksson, L. Koranyi, R. Bourey, et al., “Insulin resistance in type 2 (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT-4) gene in human skeletal muscle,” Diabetologia, vol. 35, no. 2, pp. 143–147, 1992.
  192. R. C. Bonadonna, S. Del Prato, M. P. Saccomani, et al., “Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes,” The Journal of Clinical Investigation, vol. 92, no. 1, pp. 486–494, 1993.
  193. R. C. Bonadonna, S. Del Prato, E. Bonora, et al., “Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM,” Diabetes, vol. 45, supplement 3, pp. 915–925, 1996.
  194. G. W. Cline, K. F. Petersen, M. Krssak, et al., “Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes,” The New England Journal of Medicine, vol. 341, no. 4, pp. 240–246, 1999. View at Publisher · View at Google Scholar
  195. K. V. Williams, J. C. Price, and D. E. Kelley, “Interactions of impaired glucose transport and phosphorylation in skeletal muscle insulin resistance. A dose-response assessment using positron emission tomography,” Diabetes, vol. 50, no. 9, pp. 2069–2079, 2001.
  196. W.-H. Choi, S. O'Rahilly, J. B. Buse, et al., “Molecular scanning of insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects,” Diabetes, vol. 40, no. 12, pp. 1712–1718, 1991.
  197. L. M. Perriott, T. Kono, R. R. Whitesell, et al., “Glucose uptake and metabolism by cultured human skeletal muscle cells: rate-limiting steps,” American Journal of Physiology, vol. 281, no. 1, pp. E72–E80, 2001.
  198. R. L. Printz, H. Ardehali, S. Koch, and D. K. Granner, “Human hexokinase II mRNA and gene structure,” Diabetes, vol. 44, no. 3, pp. 290–294, 1995.
  199. C. Vogt, H. Ardehali, P. Iozzo, et al., “Regulation of hexokinase II expression in human skeletal muscle in vivo,” Metabolism, vol. 49, no. 6, pp. 814–818, 2000.
  200. M. Pendergrass, J. Koval, C. Vogt, et al., “Insulin-induced hexokinase II expression is reduced in obesity and NIDDM,” Diabetes, vol. 47, no. 3, pp. 387–394, 1998. View at Publisher · View at Google Scholar
  201. L. J. Mandarino, R. L. Printz, K. A. Cusi, et al., “Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle,” American Journal of Physiology, vol. 269, no. 4, pp. E701–E708, 1995. View at Scopus
  202. P.-H. Ducluzeau, N. Perretti, M. Laville, et al., “Regulation by insulin of gene expression in human skeletal muscle and adipose tissue: evidence for specific defects in type 2 diabetes,” Diabetes, vol. 50, no. 5, pp. 1134–1142, 2001.
  203. M. Lehto, X. Huang, E. M. Davis, et al., “Human hexokinase II gene: exon-intron organization, mutation screening in NIDDM, and its relationship to muscle hexokinase activity,” Diabetologia, vol. 38, no. 12, pp. 1466–1474, 1995. View at Publisher · View at Google Scholar
  204. M. Laakso, M. Malkki, P. Kekalainen, J. Kuusisto, and S. S. Deeb, “Polymorphisms of the human hexokinase II gene: lack of association with NIDDM and insulin resistance,” Diabetologia, vol. 38, no. 5, pp. 617–622, 1995. View at Publisher · View at Google Scholar
  205. S. M. Echwald, C. Bjorbaek, T. Hansen, et al., “Identification of four amino acid substitutions in hexokinase II and studies of relationships to NIDDM, glucose effectiveness, and insulin sensitivity,” Diabetes, vol. 44, no. 3, pp. 347–353, 1995.
  206. G. Gulli, E. Ferrannini, M. Stern, S. Haffner, and R. A. DeFronzo, “The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents,” Diabetes, vol. 41, no. 12, pp. 1575–1586, 1992.
  207. A. Golay, R. A. DeFronzo, E. Ferrannini, et al., “Oxidative and non-oxidative glucose metabolism in non-obese type 2 (non-insulin-dependent) diabetic patients,” Diabetologia, vol. 31, no. 8, pp. 585–591, 1988.
  208. S. Lillioja, D. M. Mott, J. K. Zawadzki, A. A. Young, W. G. Abbott, and C. Bogardus, “Glucose storage is a major determinant of in vivo ‘insulin resistance’ in subjects with normal glucose tolerance,” Journal of Clinical Endocrinology and Metabolism, vol. 62, no. 5, pp. 922–927, 1986.
  209. G. I. Shulman, D. L. Rothman, T. Jue, P. Stein, R. A. DeFronzo, and R. G. Shulman, “Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy,” The New England Journal of Medicine, vol. 322, no. 4, pp. 223–228, 1990.
  210. D. L. Rothman, I. Magnusson, G. Cline, et al., “Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 4, pp. 983–987, 1995. View at Publisher · View at Google Scholar
  211. A. Vaag, J. E. Henriksen, S. Madsbad, N. Holm, and H. Beck-Nielsen, “Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus,” The Journal of Clinical Investigation, vol. 95, no. 2, pp. 690–698, 1995.
  212. H. Yki-Jarvinen, D. Mott, A. A. Young, K. Stone, and C. Bogardus, “Regulation of glycogen synthase and phosphorylase activities by glucose and insulin in human skeletal muscle,” The Journal of Clinical Investigation, vol. 80, no. 1, pp. 95–100, 1987.
  213. S. Frame and P. Cohen, “GSK3 takes centre stage more than 20 years after its discovery,” Biochemical Journal, vol. 359, part 1, pp. 1–16, 2001. View at Publisher · View at Google Scholar
  214. P. Cohen, “The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction,” Philosophical Transactions of the Royal Society B, vol. 354, no. 1382, pp. 485–495, 1999.
  215. P. Damsbo, A. Vaag, O. Hother-Nielsen, and H. Beck-Nielsen, “Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus,” Diabetologia, vol. 34, no. 4, pp. 239–245, 1991.
  216. L. J. Mandarino, K. S. Wright, L. S. Verity, et al., “Effects of insulin infusion on human skeletal muscle pyruvate dehydrogenase, phosphofructokinase, and glycogen synthase: evidence for their role in oxidative and nonoxidative glucose metabolism,” The Journal of Clinical Investigation, vol. 80, no. 3, pp. 655–663, 1987.
  217. A. W. Thorburn, B. Gumbiner, F. Bulacan, P. Wallace, and R. R. Henry, “Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake,” The Journal of Clinical Investigation, vol. 85, no. 2, pp. 522–529, 1990.
  218. A. Vaag, J. E. Henriksen, and H. Beck-Nielsen, “Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus,” The Journal of Clinical Investigation, vol. 89, no. 3, pp. 782–788, 1992.
  219. B. L. Nyomba, D. Freymond, I. Raz, K. Stone, D. M. Mott, and C. Bogardus, “Skeletal muscle glycogen synthase activity in subjects with non-insulin-dependent diabetes mellitus after glyburide therapy,” Metabolism, vol. 39, no. 11, pp. 1204–1210, 1990. View at Publisher · View at Google Scholar
  220. T. Pratipanawatr, K. Cusi, P. Ngo, W. Pratipanawatr, L. J. Mandarine, and R. A. DeFronzo, “Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes,” Diabetes, vol. 51, no. 2, pp. 462–468, 2002.
  221. H. Vestergaard, S. Lund, F. S. Larsen, O. J. Bjerrum, and O. Pedersen, “Glycogen synthase and phosphofructokinase protein and mRNA levels in skeletal muscle from insulin-resistant patients with non-insulin-dependent diabetes mellitus,” The Journal of Clinical Investigation, vol. 91, no. 6, pp. 2342–2350, 1993.
  222. H. Vestergaard, C. Bjorbaek, P. H. Andersen, J. F. Bak, and O. Pedersen, “Impaired expression of glycogen synthase mRNA in skeletal muscle of NIDDM patients,” Diabetes, vol. 40, no. 12, pp. 1740–1745, 1991.
  223. M. Majer, D. M. Mott, H. Mochizuki, et al., “Association of the glycogen synthase locus on 19q13 with NIDDM in Pima Indians,” Diabetologia, vol. 39, no. 3, pp. 314–321, 1996. View at Publisher · View at Google Scholar
  224. M. Orho, P. Nikula-Ijas, C. Schalin-Jantti, M. A. Permutt, and L. C. Groop, “Isolation and characterization of the human muscle glycogen synthase gene,” Diabetes, vol. 44, no. 9, pp. 1099–1105, 1995.
  225. C. Bjørbæk, S. M. Echwald, P. Hubricht, et al., “Genetic variants in promoters and coding regions of the muscle glycogen synthase and the insulin-responsive GLUT4 genes in NIDDM,” Diabetes, vol. 43, no. 8, pp. 976–983, 1994.
  226. C. Bjørbæk, T. A. Vik, S. M. Echwald, et al., “Cloning of a human insulin-stimulated protein kinase (ISPK-1) gene and analysis of coding regions and mRNA levels of the ISPK-1 and the protein phosphatase-1 genes in muscle from NIDDM patients,” Diabetes, vol. 44, no. 1, pp. 90–97, 1995.
  227. M. Prochazka, H. Mochizuki, L. J. Baier, P. T. W. Cohen, and C. Bogardus, “Molecular and linkage analysis of type-1 protein phosphatase catalytic beta-subunit gene: lack of evidence for its major role in insulin a resistance in Pima Indians,” Diabetologia, vol. 38, no. 4, pp. 461–466, 1995. View at Publisher · View at Google Scholar
  228. C. Schalin-Jantti, M. Harkonen, and L. C. Groop, “Impaired activation of glycogen synthase in people at increased risk for developing NIDDM,” Diabetes, vol. 41, no. 5, pp. 598–604, 1992.
  229. S. Del Prato, R. C. Bonadonna, E. Bonora, et al., “Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus,” The Journal of Clinical Investigation, vol. 91, no. 2, pp. 484–494, 1993.
  230. K. Falholt, I. Jensen, S. Lindkaer Jensen, et al., “Carbohydrate and lipid metabolism of skeletal muscle in type 2 diabetic patients,” Diabetic Medicine, vol. 5, no. 1, pp. 27–31, 1988.
  231. L. J. Mandarino, Z. Madar, O. G. Kolterman, J. M. Bell, and J. M. Olefsky, “Adipocyte glycogen synthase and pyruvate dehydrogenase in obese and type II diabetic subjects,” American Journal of Physiology, vol. 251, no. 4, pp. E489–E496, 1986.
  232. D. E. Kelley, M. Mokan, and L. J. Mandarino, “Intracellular defects in glucose metabolism in obese patients with NIDDM,” Diabetes, vol. 41, no. 6, pp. 698–706, 1992.
  233. L. C. Groop, R. C. Bonadonna, D. C. Simonson, A. S. Petrides, M. Shank, and R. A. DeFronzo, “Effect of insulin on oxidative and nonoxidative pathways of free fatty acid metabolism in human obesity,” American Journal of Physiology, vol. 263, no. 1, pp. E79–E84, 1992.
  234. P. J. Randle, P. B. Garland, C. N. Hales, and E. A. Newsholme, “The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus,” The Lancet, vol. 281, no. 7285, pp. 785–789, 1963.